Cogent Biosciences IncCOGT
ASignal's systematic analysis rates COGT as Neutral.
Reflects the latest available analysis · analyzed Aug 27, 2026
The case on COGT
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Oversold RSI at 28.9 suggests potential reversal
- Strong liquidity position with current ratio of 13.57x
- Low debt-to-equity ratio of 0.46x
- High cash reserves of $792.30M
- Trading below 20-day and 50-day moving averages, indicating pullback
- Negative MACD histogram indicates weakening momentum
- Negative price momentum and trading below Bollinger middle band
- Negative return on equity (-109.74%) and return on assets (-43.84%)
- Negative operating and free cash flow
- No profitability with zero operating and net margins
- Forward P/E of -33.13x and negative EV/EBITDA suggest valuation challenges
See the full verdict on COGT
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes COGT
Most investors never get a second opinion, let alone several. ASignal runs COGT past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.